Androgenetic alopecia, a slow progressive form of alopecia, begins after the onset of puberty. Pattern or androgenetic alopecia is a genetically predetermined disorder due to excessive response to androgens that affects up to 50% of males and females globally, according to the National Center for Biotechnology Information (NCBI). It is characterized by progressive loss of terminal hair of the scalp, in a characteristic distribution in both males and females. In males, hair loss is most prominent in the vertex and frontotemporal regions, while in women the frontal hairline is typically spared with diffuse apical hair loss noted as a wider anterior part of the hair.
Rising incidence of androgenetic alopecia is expected to drive the global androgenetic alopecia treatment market growth. According to the National Library of Medicine (NLM), a medical library which is part of the National Institutes of Health (NIH), androgenetic alopecia affects approximately 50 million men and 30 million women in the U.S.
However, availability of alternative treatments is expected to hinder the market growth. For instance, hair restoration surgery such as scalp reduction surgeries, which is not used frequently but efficacy of hair transplantation is based on the principle of donor dominance.
- This report provides in-depth analysis of the global androgenetic alopecia treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global androgenetic alopecia treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd. among others
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global androgenetic alopecia treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global androgenetic alopecia treatment market.
-
- Topical Agents
- 5 AR Inhibitors
- Others
-
-
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Histogen Inc.
- Cipla Limited
- Aclaris Therapeutics, Inc.
- Merck & Co., Inc.
- Daiichi-Sankyo Co., Ltd.
- Johnson and Johnson Services, Inc.
- Lexington International LLC
- Vita-Cos-Med Klett-Loch GmbH
- PureTech
- Vitabiotics
- Reddy’s Laboratories
- HCell Inc.
- Follica, Inc.
- Ranbaxy Laboratories Ltd.
